February 2017

New Product - Belsomra

Belsomra (suvorexant) is a highly selective reversible high affinity orexin receptor antagonist at OX1R (K_i 0.55 nM) and OX2R (K_i 0.35 nM) receptors. Blocking the binding of wake promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive. Belsomra is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Following initiation of treatment, continuation should be re-evaluated after 3 months. Belsomra is contraindicated in patients with narcolepsy. Belsomra is available as 15 mg and 20 mg tablets in blister packs of 30’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au